ARIA/NVS/BMY—The possibility of some patients being able to stop TKI treatment (specifically Tasigna) without incurring a relapse was mentioned on NVS’ 2Q12 CC (#msg-77720983). It’s a pretty big deal for the CML market if this idea pans out in clinical trials; as an ARIA investor, you should be hoping it doesn’t.
News 
Market Data 
Discover 
